Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Laboratory Corp (NYSE: LH) on July 9 and set a price target of $196. The company’s shares opened today at $186, close to its 52-week high of $190.36.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.4% and a 63.4% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Idexx Laboratories, and Exact Sciences.
Currently, the analyst consensus on Laboratory Corp is a Moderate Buy with an average price target of $206.50.
See today’s analyst top recommended stocks >>
Laboratory Corp’s market cap is currently $18.83B and has a P/E ratio of 15.31. The company has a Price to Book ratio of 2.70.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. Last month, Edward Dodson, the CAO of LH sold 13,000 shares for a total of $2,383,550.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.
